Scarica l'app Stockscreener
89.32
0.96%
0.85
Dopo l'orario di chiusura:
89.29
-0.03
-0.03%
Precedente Chiudi:
$88.47
Aprire:
$88.47
Volume 24 ore:
764.98K
Relative Volume:
0.75
Capitalizzazione di mercato:
$6.66B
Reddito:
-
Utile/perdita netta:
$-255.84M
Rapporto P/E:
-21.19
EPS:
-4.2149
Flusso di cassa netto:
$-232.60M
1 W Prestazione:
+7.46%
1M Prestazione:
+24.23%
6M Prestazione:
+59.93%
1 anno Prestazione:
+171.90%
Intervallo 1D:
$86.07
$89.69
Intervallo di 1 settimana:
$82.64
$89.69
Portata 52W:
$31.38
$89.69
Apogee Therapeutics Inc Stock (APGE) Company Profile
Nome
Apogee Therapeutics Inc
Settore
Industria
Telefono
650-394-5230
Indirizzo
221 CRESCENT ST., WALTHAM
Compare APGE vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
APGE
Apogee Therapeutics Inc
|
89.32 | 6.60B | 0 | -255.84M | -232.60M | -4.2149 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Apogee Therapeutics Inc Stock (APGE) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-18 | Iniziato | Truist | Hold |
| 2026-01-22 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2026-01-07 | Iniziato | Wolfe Research | Peer Perform |
| 2025-12-17 | Iniziato | Stephens | Overweight |
| 2025-12-10 | Iniziato | Deutsche Bank | Buy |
| 2025-11-03 | Iniziato | Craig Hallum | Buy |
| 2025-10-21 | Iniziato | Mizuho | Outperform |
| 2025-09-25 | Iniziato | RBC Capital Mkts | Outperform |
| 2025-07-07 | Reiterato | BTIG Research | Buy |
| 2025-03-13 | Iniziato | Citigroup | Buy |
| 2024-11-25 | Iniziato | Canaccord Genuity | Buy |
| 2024-05-10 | Iniziato | BofA Securities | Buy |
| 2023-12-20 | Iniziato | BTIG Research | Buy |
| 2023-08-08 | Iniziato | Guggenheim | Buy |
| 2023-08-08 | Iniziato | Jefferies | Buy |
| 2023-08-08 | Iniziato | Stifel | Buy |
| 2023-08-08 | Iniziato | TD Cowen | Outperform |
| 2023-08-08 | Iniziato | Wedbush | Outperform |
Mostra tutto
Apogee Therapeutics Inc Borsa (APGE) Ultime notizie
APGE stock up as skin disease drug shows sustained 52-week efficacy - MSN
Apogee Therapeutics rises on positive phase 2 data for Zumilokibart in atopic dermatitis - MSN
(APGE) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Apogee Therapeutics Insider Sold Shares Worth $1,651,664, According to a Recent SEC Filing - Moomoo
How Investors May Respond To Apogee Therapeutics (APGE) CEO Share Sale and US$403 Million Equity Raise - Sahm
Aug PreEarnings: Will Apogee Therapeutics Inc benefit from seasonalityPortfolio Return Report & Expert Approved Trade Ideas - baoquankhu1.vn
Dow Update: Should value investors consider Apogee Therapeutics IncQuarterly Market Summary & Accurate Technical Buy Alerts - baoquankhu1.vn
Apogee Therapeutics CEO Henderson sells $1.65 million in stock By Investing.com - Investing.com Australia
Apogee Therapeutics CEO Henderson sells $1.65 million in stock - Investing.com
Apogee Therapeutics (APGE) CEO sells 20,000 shares under Rule 10b5-1 plan - Stock Titan
Apogee Therapeutics stock hits all-time high at 85.95 USD By Investing.com - Investing.com Australia
Apogee Therapeutics stock hits all-time high at 85.95 USD - Investing.com
T. Rowe Price (APGE) discloses 10.29M shares, 16.8% stake in Apogee - Stock Titan
Trade Recap: Whats the beta of Apogee Therapeutics Inc stockWatch List & Fast Moving Stock Watchlists - baoquankhu1.vn
APGE Earnings History & Surprises | EPS & Revenue Results | APOGEE THERAPEUTICS INC (NASDAQ:APGE) - ChartMill
Insider Sell: Jane Henderson Sells 2,000 Shares of Apogee Therapeutics Inc (APGE) - GuruFocus
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 By Investing.com - Investing.com Canada
Apogee Therapeutics (APGE) CMO sells shares worth $466,619 - Investing.com
Insider Selling: Apogee Therapeutics (NASDAQ:APGE) Insider Sells 5,500 Shares of Stock - MarketBeat
Apogee Therapeutics (APGE) CMO trades 5,500 shares under 10b5-1 plan - Stock Titan
Responsive Playbooks and the APGE Inflection - Stock Traders Daily
APGE Technical Analysis & Stock Price Forecast - Intellectia AI
Mizuho Initiates Coverage of Apogee Therapeutics (APGE) with Outperform Recommendation - MSN
Banque Pictet & Cie SA Invests $3.16 Million in Apogee Therapeutics Inc. $APGE - MarketBeat
Apogee Therapeutics CMO sells $361,860 in shares - Investing.com
Deutsche Bank Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $118 - Moomoo
SG Americas Securities LLC Sells 60,964 Shares of Apogee Therapeutics Inc. $APGE - marketbeat.com
Fairmount Funds Management LLC Increases Stake in Apogee Therape - GuruFocus
Apogee Therapeutics (NASDAQ:APGE) Sets New 52-Week HighHere's What Happened - MarketBeat
Apogee Therapeutics prices upsized $350M offering at $70 a share - MSN
BTIG Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Maintains Target Price $137 - Moomoo
APGE Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Market Rankings: Will Apogee Therapeutics Inc benefit from seasonalityEarnings Recap Summary & Weekly Setup with ROI Potential - baoquankhu1.vn
Should Apogee Therapeutics’ (APGE) Infrequent-Dosing AD Data and $403M Equity Raise Require Investor Action? - simplywall.st
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target By Investing.com - Investing.com South Africa
BTIG reiterates Buy on Apogee Therapeutics stock, $137 target - Investing.com
Apogee Therapeutics (NASDAQ:APGE) Price Target Raised to $110.00 at Mizuho - MarketBeat
Mizuho raises Apogee Therapeutics stock price target on AD data By Investing.com - Investing.com South Africa
Mizuho raises Apogee Therapeutics stock price target on AD data - Investing.com
Mizuho Securities Maintains Apogee Therapeutics(APGE.US) With Buy Rating, Raises Target Price to $110 - Moomoo
Apogee Therapeutics Inc Azioni (APGE) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
2.69%
0.25%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):